Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ibuprofen + gabapentin
- Development stage
- Unknown
- Lead developer
- Medical University of Plovdiv
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Ibuprofen + gabapentin is a combination therapy consisting of the nonsteroidal anti-inflammatory drug (NSAID) ibuprofen and the gabapentinoid anticonvulsant gabapentin. Ibuprofen acts as a non-selective inhibitor of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, which reduces the synthesis of prostaglandins involved in pain and inflammation. Gabapentin binds with high affinity to the alpha-2-delta-1 subunit of voltage-gated calcium channels in the central nervous system, modulating the release of excitatory neurotransmitters such as glutamate and substance P. This combination is primarily investigated for the management of postoperative pain, neuroinflammation, and anxiety, particularly following surgical procedures like the removal of impacted mandibular third molars. By targeting both peripheral inflammatory pathways and central pain processing mechanisms, the combination aims to provide superior analgesia compared to monotherapy.
- Other names
- ibuprofen/gabapentingabapentin/ibuprofen
02
Targets
CACNA2D2 (α2δ-2)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)CACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)PGHS-1 (Prostaglandin G/H Synthase 1)
Beyond the preview
Go deeper on ibuprofen + gabapentin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ibuprofen + gabapentin.